In the last trading session, 1.45 million shares of the Atai Life Sciences N.V. (NASDAQ:ATAI) were traded. Most recently the company’s share price was $1.88, and it changed around -$0.08 or -4.08% from the last close, which brings the market valuation of the company to $308.81M. ATAI currently trades at a discount to its 52-week high of $4.96, offering almost -163.83% off that amount. The share price’s 52-week low was $1.14, which indicates that the current value has risen by an impressive 39.36% since then. We note from Atai Life Sciences N.V.’s average daily trading volume that its 10-day average is 0.7 million shares, with the 3-month average coming to 1.16 million.
Atai Life Sciences N.V. stock received a consensus recommendation rating of a Buy, based on a mean score of 1.80. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended ATAI as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Atai Life Sciences N.V. is expected to report earnings per share of -$0.21 for the current quarter.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Atai Life Sciences N.V. (NASDAQ:ATAI) trade information
Instantly ATAI has showed a red trend with a performance of -4.08% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.0600 on Tuesday, 05/23/23 increased the stock’s daily price by 8.74%. The company’s shares are currently down -29.32% year-to-date, but still down -3.09% over the last five days. On the other hand, Atai Life Sciences N.V. (NASDAQ:ATAI) is -4.57% down in the 30-day period. We can see from the shorts that 5.3 million shares have been sold at a short interest cover period of 3.15 day(s).
The consensus price target as assigned by Wall Street analysts is $12.30, which translates to bulls needing to increase their stock price by 84.72% from its current value. Analyst projections state that ATAI is forecast to be at a low of $6.00 and a high of $21.00. In order for the stock price to hit the forecast high, the stock would need to plunge -1017.02% from its current level, while the stock would need to crash -219.15% from its current level to reach the projected low.
Atai Life Sciences N.V. (ATAI) estimates and forecasts
Atai Life Sciences N.V. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -38.76 percent over the past six months and at a 12.24% annual growth rate that is well above the industry average of 6.10%. Moreover, analysts have decided to roll up on their fiscal year 2023 revenue estimates. The rating firms predict that it will gain 12.50% in revenue this quarter, and will report an increase of 4.50% in the next quarter. The year-over-year growth rate is expected to be -39.90%, down from the previous year.
The company’s sales for the same quarters a year ago were $170k and $24k respectively.
Atai Life Sciences N.V.’s next quarterly earnings report is expected to be released on May 11.
Atai Life Sciences N.V. (NASDAQ:ATAI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.27% of Atai Life Sciences N.V. shares, and 31.44% of them are in the hands of institutional investors. The stock currently has a share float of 34.65%. Atai Life Sciences N.V. stock is held by 147 institutions, with Morgan Stanley being the largest institutional investor. By Mar 30, 2023, it held 1.41% of the shares, which is about 2.34 million shares worth $4.39 million.
Blackrock Inc., with 1.28% or 2.12 million shares worth $3.99 million as of Mar 30, 2023, holds the second largest percentage of outstanding shares.
iShares NASDAQ Biotechnology ETF and Morgan Stanley Inst Fund Inc-Inception Port were the top two Mutual Funds as of Feb 27, 2023. The former held 0.97 million shares worth $1.83 million, making up 0.59% of all outstanding shares. On the other hand, Morgan Stanley Inst Fund Inc-Inception Port held roughly 0.55 million shares worth around $1.03 million, which represents about 0.33% of the total shares outstanding.